Advertisement
Advertisement
JBIO
J
Jade Biosciences, Inc. Common Stock
14.06
USDSponsored
+0.29
+2.07%
Mar 19, 16:00 UTC -4
Closed
After-Market
14.06
0.00
0.00%
JBIO Earnings Reports
Positive Surprise Ratio
JBIO beat 6 of 19 last estimates.
32%
Next Report
Date of Next Report
Apr 20, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.48
Implied change from Q4 25 (Revenue/ EPS)
--
/-18.64%
Implied change from Q1 25 (Revenue/ EPS)
--
/-84.76%
Jade Biosciences, Inc. Common Stock earnings per share and revenue
On Mar 06, 2026, JBIO reported earnings of -0.59 USD per share (EPS) for Q4 25, missing the estimate of -0.48 USD, resulting in a -21.96% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.22% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.48 USD, with revenue projected to reach -- USD, implying an decrease of -18.64% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Trevi Therapeutics, Inc. Common Stock
Report Date
Mar 17, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.06
Surprise
+40.06%
CytomX Therapeutics, Inc.
Report Date
Mar 16, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.22
Surprise
-130.37%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Mar 16, 2026 For Q4 25
Estimate
-$0.53
Actual
-$0.50
Surprise
+7.29%
Alvotech Ordinary Shares
Report Date
Mar 18, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.37
Surprise
-706.10%
XOMA Royalty Corporation Common Stock
Report Date
Mar 18, 2026 For Q4 25
Estimate
-$0.15
Actual
$0.12
Surprise
+175.90%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Abeona Therapeutics Inc. Common Stock
Report Date
Mar 17, 2026 For Q4 25
Estimate
-$0.36
Actual
-$0.34
Surprise
+6.28%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Mar 18, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.07
Surprise
-1472.55%
Artiva Biotherapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.84
Actual
-Surprise
-
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
FAQ
What were Jade Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Jade Biosciences, Inc. Common Stock reported EPS of -$0.59, missing estimates by -21.96%, and revenue of $0.00, 0% as expectations.
How did the market react to Jade Biosciences, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 1.22%, changed from $13.88 before the earnings release to $14.05 the day after.
When is Jade Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for Apr 20, 2026.
What are the forecasts for Jade Biosciences, Inc. Common Stock's next earnings report?
Based on 6
analysts, Jade Biosciences, Inc. Common Stock is expected to report EPS of -$0.48 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement